ERBB2 and breast cancer: This subtype of breast cancer is of interest in terms of outcome as anti-HER2-targeted therapies, particularly trastuzumab (Herceptine), have represented a breakthrough in their treatment.3 Further understanding of the mechanism(s) related to HER2 amplification may lead to the development of new therapeutic targets.